378 related articles for article (PubMed ID: 31562203)
1. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
[TBL] [Abstract][Full Text] [Related]
2. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of EZH2 (Enhancer of Zeste Homolog 2) Attenuates Neuroinflammation via H3k27me3/SOCS3/TRAF6/NF-κB (Trimethylation of Histone 3 Lysine 27/Suppressor of Cytokine Signaling 3/Tumor Necrosis Factor Receptor Family 6/Nuclear Factor-κB) in a Rat Model of Subarachnoid Hemorrhage.
Luo Y; Fang Y; Kang R; Lenahan C; Gamdzyk M; Zhang Z; Okada T; Tang J; Chen S; Zhang JH
Stroke; 2020 Nov; 51(11):3320-3331. PubMed ID: 32933418
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.
Huang B; Mu P; Yu Y; Zhu W; Jiang T; Deng R; Feng G; Wen J; Zhu X; Deng Y
Gastric Cancer; 2021 Jan; 24(1):72-84. PubMed ID: 32529327
[TBL] [Abstract][Full Text] [Related]
5. [Effects and molecular mechanism of histone methyltransferase enhancer of zeste homolog 2 on regulating sepsis-induced T cell dysfunction].
Li Z; Zhao D; Zhou X; Tang L
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Apr; 34(4):357-361. PubMed ID: 35692198
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
Kong Y; Zhang Y; Mao F; Zhang Z; Li Z; Wang R; Liu J; Liu X
Mol Cancer Ther; 2020 Dec; 19(12):2490-2501. PubMed ID: 33024029
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor.
Zhang T; Guo Z; Huo X; Gong Y; Li C; Huang J; Wang Y; Feng H; Ma X; Jiang C; Yin Q; Xue L
EBioMedicine; 2022 Mar; 77():103872. PubMed ID: 35158113
[TBL] [Abstract][Full Text] [Related]
8. Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
Saito S; Kono M; Nguyen HCB; Egloff AM; Messier C; Lizotte P; Paweletz C; Adkins D; Uppaluri R
Clin Cancer Res; 2024 May; 30(9):1934-1944. PubMed ID: 38372707
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer.
Hsieh MS; Ling HH; Setiawan SA; Hardianti MS; Fong IH; Yeh CT; Chen JH
Chem Biol Interact; 2024 May; 395():111004. PubMed ID: 38636790
[TBL] [Abstract][Full Text] [Related]
10. EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
Zong X; Wang W; Ozes A; Fang F; Sandusky GE; Nephew KP
Cancer Res; 2020 Oct; 80(20):4371-4385. PubMed ID: 32816909
[TBL] [Abstract][Full Text] [Related]
11. Interplay between EZH2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets.
Milan TM; Eskenazi APE; Oliveira LD; Silva GD; Bighetti-Trevisan RL; Freitas GP; Almeida LO
Cell Signal; 2023 Sep; 109():110773. PubMed ID: 37331417
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
Ratz L; Brambillasca C; Bartke L; Huetzen MA; Goergens J; Leidecker O; Jachimowicz RD; van de Ven M; Proost N; Siteur B; de Korte-Grimmerink R; Bouwman P; Pulver EM; de Bruijn R; Isensee J; Hucho T; Pandey G; van Lohuizen M; Mallmann P; Reinhardt HC; Jonkers J; Puppe J
Breast Cancer Res; 2022 Jun; 24(1):41. PubMed ID: 35715861
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC.
Liu J; Lin WP; Su W; Wu ZZ; Yang QC; Wang S; Sun TG; Huang CF; Wang XL; Sun ZJ
Int Immunopharmacol; 2023 Jun; 119():110243. PubMed ID: 37137265
[TBL] [Abstract][Full Text] [Related]
14. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
Knutson SK; Warholic NM; Johnston LD; Klaus CR; Wigle TJ; Iwanowicz D; Littlefield BA; Porter-Scott M; Smith JJ; Moyer MP; Copeland RA; Pollock RM; Kuntz KW; Raimondi A; Keilhack H
PLoS One; 2014; 9(12):e111840. PubMed ID: 25493630
[TBL] [Abstract][Full Text] [Related]
16. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
[TBL] [Abstract][Full Text] [Related]
18. EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine.
Barazeghi E; Hellman P; Norlén O; Westin G; Stålberg P
Sci Rep; 2021 Nov; 11(1):22733. PubMed ID: 34815475
[TBL] [Abstract][Full Text] [Related]
19. A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells.
Huang K; Sun R; Chen J; Yang Q; Wang Y; Zhang Y; Xie K; Zhang T; Li R; Zhao Q; Zou L; Li J
Cell Cycle; 2020 Apr; 19(7):758-771. PubMed ID: 32093567
[TBL] [Abstract][Full Text] [Related]
20. EZH2 Expression in Head-and-Neck Squamous Cell Cancer in Young Patients.
Révész M; Oberna F; Slezák A; Tóth E; Ferenczi Ö; Kenessey I; Takácsi-Nagy Z
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]